SEC receives Daxor Corp's application to deregister as an investment company
Daxor Corp., a Nasdaq-listed radiopharmaceutical and medical-device maker, seeks SEC order ending its investment-company registration; a hearing request must be filed by Nov. 30, 2026.
The Securities and Exchange Commission issued a notice of application on September 4, 2026 (Release No. IC-36320) for Daxor Corporation. The applicant requests an order declaring that it has ceased to be an investment company under section 8(f) of the Investment Company Act of 1940. An order will be entered unless the Commission orders a hearing.
The original application was filed on February 9, 2026 and subsequently amended on May 21, 2026; June 17, 2026; September 4, 2026; and October 9, 2026. Interested parties may request a hearing by emailing the SEC's Secretary and serving the applicant, with requests due by 5:30 p.m., Eastern time, on November 30, 2026, accompanied by proof of service.
Daxor, incorporated in New York as Iatric Corporation in May 1971 and renamed Daxor Corporation in May 1973, now operates as a radiopharmaceutical and medical-device manufacturer selling Volumex Test Kits used with its BVA Companion Analyzer. The company states it held no investment securities as of December 31, 2025 and at the filing of its second amended application. Its investment securities represented approximately 3.11 % of total assets on December 31, 2024 and 1.10 % on June 30, 2025, after which the holdings were liquidated.
The applicant affirms it will continue to comply with the reporting requirements of Section 13(a) of the Securities Exchange Act of 1934, filing Forms 10-K, 10-Q and 8-K. Its common stock trades on Nasdaq under the symbol DXR, with an authorized share count of 10,000,000 as of May 19, 2025. Ongoing litigation concerning alleged intellectual-property misappropriation is described as immaterial to the determination of investment-company status.
For further information, SEC contacts are Adam M. Large, Senior Special Counsel, and Thomas M. Ahmadifar, Branch Chief. The applicant may be reached through Robert J. Michel, Daxor Corporation, Oak Ridge, TN, and counsel Peter D. Fetzer of Foley & Lardner LLP, Milwaukee, WI. The complete application is available on the SEC's website via file number 811-22684.
Further reading